MediWound Ltd.
MDWD
Rank in Stocks
#17088
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and... MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Share Price
$14.08
Last synced: 2026-11-09
Market Cap
$181.78M
Change (1 day)
-1.19%
Change (1 year)
-23.97%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade MediWound Ltd. (MDWD)
Category
Healthcare
Operating Margin for MediWound Ltd. (MDWD)
Operating Margin as of November 2026 TTM: -267.86%
According to MediWound Ltd.'s latest financial reports, its current operating margin (TTM) is -267.86%. At the end of 2025 the company had an operating margin of -149.06%.
Operating Margin history for MediWound Ltd. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -267.86% | 79.70% |
| 2025 | -149.06% | 55.51% |
| 2024 | -95.85% | 15.54% |
| 2023 | -82.96% | 186.96% |
| 2022 | -28.91% | -38.78% |
| 2021 | -47.22% | 16.25% |
| 2020 | -40.62% | -327.95% |
| 2019 | 17.82% | -105.64% |
| 2018 | -315.97% | -42.38% |
| 2017 | -548.36% | -57.61% |
| 2016 | -1,293.65% | -63.37% |
| 2015 | -3,531.95% | -57.31% |
| 2014 | -8,272.97% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.14% |
US
|
|
| -149.01% | -99.44% |
US
|
|
| 25.57% | -100.10% |
AU
|
|
| 31.23% | -100.12% |
BE
|
|
| 29.35% | -100.11% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about MediWound Ltd.'s operating margin
What is MediWound Ltd.'s operating margin?
MediWound Ltd.'s operating margin is -267.86%, as of Nov 2026.
What was MediWound Ltd.'s operating margin in 2025?
In 2025, MediWound Ltd.'s operating margin was -149.06%, compared with -95.85% in 2024.
How has MediWound Ltd.'s operating margin changed since 2020?
From 2020 to 2025, MediWound Ltd.'s operating margin was highest in 2022 (-28.91%) and lowest in 2025 (-149.06%).
How does MediWound Ltd.'s operating margin compare with similar companies?
MediWound Ltd.'s operating margin (-267.86%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.